• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Mind Medicine (MindMed) Inc.

    10/6/22 1:33:35 PM ET
    $MNMD
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $MNMD alert in real time by email
    SC 13G 1 tm2227574d1_sc13g.htm SC 13G

     

    CUSIP No:     60255C885

     

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    SCHEDULE 13G

     

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO § 240.13d-2.

     

    (Amendment No. ____) *

     

    Mind Medicine (MindMed) Inc.

    (Name of Issuer)

     

    Common Shares, no par value

    (Title of Class of Securities)

     

    60255C885

    (CUSIP Number)

     

    September 27, 2022

    (Date of Event Which Requires Filing of this statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨Rule 13d-1(b)
    xRule 13d-1(c)
    ¨Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No:     60255C885

     

    (1)  NAMES OF REPORTING PERSONS
     
      CVI Investments, Inc.
     
    (2)  CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)     ¨
        (b)     ¨
     
    (3)  SEC USE ONLY
     
    (4)  CITIZENSHIP OR PLACE OF ORGANIZATION
     
      Cayman Islands
       

    NUMBER OF (5) SOLE VOTING POWER
     
    SHARES 0
       
     
    BENEFICIALLY (6) SHARED VOTING POWER **
         
    OWNED BY 2,000,000
       
         
    EACH (7) SOLE DISPOSITIVE POWER
       
    REPORTING 0
       
     
    PERSON WITH (8) SHARED DISPOSITIVE POWER **
     
      2,000,000
       

    (9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
      2,000,000
     
    (10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
         ¨
     
    (11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
      5.6%
     
    (12) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
       
      CO
       

     

    ** Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and as such may exercise voting and dispositive power over these shares.

     

     

     

     

    CUSIP No:     60255C885

     

    (1)  NAMES OF REPORTING PERSONS
     
      Heights Capital Management, Inc.
     
    (2)  CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)     ¨
        (b)     ¨
     
    (3)  SEC USE ONLY
     
    (4)  CITIZENSHIP OR PLACE OF ORGANIZATION
     
      Delaware
       

    NUMBER OF (5) SOLE VOTING POWER
     
    SHARES 0
       
     
    BENEFICIALLY (6) SHARED VOTING POWER **
         
    OWNED BY 2,000,000
       
         
    EACH (7) SOLE DISPOSITIVE POWER
       
    REPORTING 0
       
     
    PERSON WITH (8) SHARED DISPOSITIVE POWER **
     
      2,000,000
       

    (9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
      2,000,000
     
    (10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
         ¨
     
    (11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
      5.6%
     
    (12) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
       
      CO
       

     

    ** Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and as such may exercise voting and dispositive power over these shares.

     

     

     

     

    CUSIP No:     60255C885

     

    Item 1.

     

    (a)Name of Issuer

     

    Mind Medicine (MindMed) Inc. (the “Company”)

     

    (b)Address of Issuer’s Principal Executive Offices

     

    One World Trade Center, Suite 8500, New York, NY 10007

     

    Item 2(a). Name of Person Filing

     

    This statement is filed by the entities listed below, who are collectively referred to herein as “Reporting Persons,” with respect to the common shares of the Company, no par value (the “Shares”).

     

    (i)CVI Investments, Inc.

     

    (ii)Heights Capital Management, Inc.

     

    Item 2(b). Address of Principal Business Office or, if none, Residence

     

    The address of the principal business office of CVI Investments, Inc. is:

     

    P.O. Box 309GT 

    Ugland House 

    South Church Street 

    George Town 

    Grand Cayman 

    KY1-1104 

    Cayman Islands

     

    The address of the principal business office of Heights Capital Management, Inc. is:

     

    101 California Street, Suite 3250 

    San Francisco, California 94111

     

    Item 2(c). Citizenship

     

    Citizenship is set forth in Row 4 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

     

    Item 2(d) Title of Class of Securities

     

    Common shares, no par value

     

    Item 2(e) CUSIP Number

     

    60255C885

     

    Item 3.If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)¨ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).

     

    (b)¨ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).

     

     

     

     

    CUSIP No:     60255C885

     

    (c)¨ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).

     

    (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

     

    (e)¨ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

     

    (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

     

    (g) ¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

     

    (h) ¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

    (i) ¨ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     

    (j)¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);

     

    (k)¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: ________________

     

    Item 4. Ownership

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    The information required by Items 4(a) – (c) is set forth in Rows 5 – 11 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

     

    The Company’s Prospectus Supplement (to Prospectus dated May 16, 2022, Registration No. 333-264648), filed on September 29, 2022, indicates there were 35,504,771 Shares outstanding (excluding Shares underlying warrants issued at the same time) as of the completion of the offering of the Shares referred to therein.

     

    Heights Capital Management, Inc., which serves as the investment manager to CVI Investments, Inc., may be deemed to be the beneficial owner of all Shares owned by CVI Investments, Inc. Each of the Reporting Persons hereby disclaims any beneficial ownership of any such Shares, except for their pecuniary interest therein.

     

    Item 5. Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ¨

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person

     

    Not applicable.

     

     

     

     

    CUSIP No:     60255C885

     

    Item 7.           Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10. Certification

     

    By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     

    CUSIP No:     60255C885

     

    SIGNATURES

     

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information with respect to it set forth in this statement is true, complete, and correct.

     

    Dated: October 6, 2022

     

    CVI INVESTMENTS, INC. HEIGHTS CAPITAL MANAGEMENT, INC.
       
    By: Heights Capital Management, Inc. pursuant to a Limited Power of Attorney, a copy of which is attached as Exhibit I hereto By: /s/ Brian Sopinsky
    Name: Brian Sopinsky
    Title: Secretary

     

    By: /s/ Brian Sopinsky  
    Name: Brian Sopinsky  
    Title: Secretary    

     

     

     

     

    CUSIP No:     60255C885

     

    EXHIBIT INDEX

     

    EXHIBIT   DESCRIPTION
    I   Limited Power of Attorney
    II   Joint Filing Agreement

     

     

     

     

    CUSIP No:     60255C885

     

    Exhibit I

     

    LIMITED POWER OF ATTORNEY

     

    THIS LIMITED POWER OF ATTORNEY given on the 16th day of July, 2015 by CVI Investments, Inc. (hereinafter called "the Company"), whose Registered Office is situated at PO Box 309GT, Ugland House, South Church Street, George Town, Grand Cayman, Cayman Islands.

     

    WHEREAS, by agreement dated July 16, 2015, by and between the Company and Heights Capital Management, Inc., the Company expressly authorized Heights Capital Management, Inc. to enter into transactions in certain designated areas as defined in the Discretionary Investment Management Agreement attached hereto marked "Appendix l."

     

    NOW THIS DEED WITNESSETH that William Walmsley, Director of the Company, hereby appoints on behalf of the Company the firm of HEIGHTS CAPITAL MANAGEMENT, INC., which through its officers, directors and employees is hereby formally granted limited power of attorney for the purpose of entering into transactions on behalf and for the account of the Company; and to take all actions on behalf of the Company as may be necessary to consummate such transactions, including but not limited to making, negotiating; signing, endorsing, executing, acknowledging and delivering in the name of the Company all applications, contracts, agreements, notes, statements, certificates, proxies and any other instruments of whatever kind and nature as may be necessary or proper in connection with the entering into of such transactions, instructing the transfer of funds where necessary with respect to such transactions, and performing all of the services specified under the Discretionary Investment Management Agreement with respect to such transactions.

     

    IN WITNESS WHEREOF, the Company has caused this Limited Power of Attorney to take effect on the day and year above written.

     

      CVI Investments, Inc.
       
      By: /s/ William Walmsley
        William Walmsley, Director

     

     

     

     

    CUSIP No:     60255C885

     

    EXHIBIT II

     

    JOINT FILING AGREEMENT

     

    This will confirm the agreement by and among the undersigned that the Schedule 13G filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the common shares of Mind Medicine (MindMed) Inc., no par value, is being filed, and all amendments thereto will be filed, on behalf of each of the persons and entities named below in accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

     

    Dated as of October 6, 2022

     

    CVI INVESTMENTS, INC. HEIGHTS CAPITAL MANAGEMENT, INC.
       
    By: Heights Capital Management, Inc. pursuant to a Limited Power of Attorney By: /s/ Brian Sopinsky
    Name: Brian Sopinsky
    Title: Secretary

     

    By: /s/ Brian Sopinsky  
    Name: Brian Sopinsky  
    Title: Secretary    

     

     

     

    Get the next $MNMD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MNMD

    DatePrice TargetRatingAnalyst
    1/28/2025$23.00Outperform
    Evercore ISI
    12/20/2024$20.00Buy
    Chardan Capital Markets
    10/14/2024$20.00Outperform
    Leerink Partners
    7/24/2024$36.00Buy
    ROTH MKM
    5/29/2024$27.00Outperform
    Robert W. Baird
    4/15/2024$20.00Outperform
    Leerink Partners
    12/5/2023$9.00Buy
    Canaccord Genuity
    12/9/2022$25.00Buy
    ROTH Capital
    More analyst ratings

    $MNMD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • MindMed to Present at the 2025 RBC Capital Markets Global Healthcare Conference

      Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that members of the Company's management team will present at the 2025 RBC Capital Markets Global Healthcare Conference: 2025 RBC Capital Markets Global Healthcare Conference Format: Fireside Chat and 1x1 Meetings Date: May 21, 2025, at 2:05 PM ET Location: New York, NY Webcast Link: 2025 RBC Capital Markets Global Healthcare Conference Audio webcasts and replays of available presentations will be accessible on MindMed's Investor Relations website for up to 90 days following

      5/13/25 7:00:00 AM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • MindMed Reports First Quarter 2025 Financial Results and Recent Business Updates

      --Dosed first patient in Emerge, the first Phase 3 study of MM120 Orally Disintegrating Tablet (ODT) in Major Depressive Disorder (MDD); 12-week topline data anticipated in 2H 2026-- --Enrollment on track in Phase 3 Voyage and Panorama studies of MM120 (ODT) in Generalized Anxiety Disorder (GAD); 12-week topline data anticipated in 1H 2026 for Voyage and 2H 2026 for Panorama-- --Company to host a conference call today at 8:00 a.m. EDT-- Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced its first quarter 2025 financial results and pro

      5/8/25 7:00:00 AM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • MindMed to Report First Quarter 2025 Financial Results on May 8, 2025

      Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it will host a live webcast at 8:00 a.m. ET on Thursday, May 8, 2025 to report financial results for the first quarter ended March 31, 2025, and discuss recent business updates. Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the Investor Relations section of the MindMed website, ir.mindmed.co, and archived for at least 30 days after the webca

      4/24/25 7:00:00 AM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care

    $MNMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Gryska David W bought $17,925 worth of shares (2,500 units at $7.17), increasing direct ownership by 14% to 19,851 units (SEC Form 4)

      4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)

      12/5/24 4:30:05 PM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Gryska David W bought $20,930 worth of shares (3,500 units at $5.98), increasing direct ownership by 25% to 17,351 units (SEC Form 4)

      4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)

      8/26/24 7:00:03 PM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Chief Executive Officer Barrow Robert bought $6,215 worth of shares (1,000 units at $6.21), increasing direct ownership by 0.18% to 565,543 units (SEC Form 4)

      4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)

      8/20/24 9:14:04 PM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care

    $MNMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Evercore ISI initiated coverage on MindMed with a new price target

      Evercore ISI initiated coverage of MindMed with a rating of Outperform and set a new price target of $23.00

      1/28/25 7:14:33 AM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Chardan Capital Markets initiated coverage on MindMed with a new price target

      Chardan Capital Markets initiated coverage of MindMed with a rating of Buy and set a new price target of $20.00

      12/20/24 7:44:37 AM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Leerink Partners resumed coverage on MindMed with a new price target

      Leerink Partners resumed coverage of MindMed with a rating of Outperform and set a new price target of $20.00

      10/14/24 7:36:33 AM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care

    $MNMD
    Leadership Updates

    Live Leadership Updates

    See more
    • MindMed Appoints Matt Wiley as Chief Commercial Officer

      Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Matt Wiley as its Chief Commercial Officer (CCO). In his new role, Mr. Wiley will serve as a member of the executive team, overseeing the Company's commercial vision and strategy as it prepares for the potential launch of its first product, MM120 orally disintegrating tablet (ODT) for generalized anxiety disorder (GAD) and major depressive disorder (MDD). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250317

      3/17/25 7:00:00 AM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • MindMed Appoints Javier Muniz, M.D., as Vice President of Research and Development Strategy

      Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Javier A. Muniz, M.D., as Vice President of Research and Development (R&D) Strategy. In his new role, Dr. Muniz will drive innovation and growth of MindMed's R&D operations as the Company prepares to initiate three Phase 3 studies of MM120 orally disintegrating tablet (ODT) in generalized anxiety disorder and major depressive disorder. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241203094211/en/Javier Muniz,

      12/3/24 7:00:00 AM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • MindMed Appoints Gregg Pratt, Ph.D. as Chief Regulatory and Quality Assurance Officer

      Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Gregg A. Pratt, Ph.D., as Chief Regulatory and Quality Assurance Officer. Dr. Pratt will serve as a member of the Executive Committee and oversee the Company's regulatory and quality functions, as well as its product registration strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241118653031/en/(Photo: Business Wire) "We are thrilled to welcome Gregg to the MindMed team. His leadership will strengthen o

      11/18/24 7:00:00 AM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care

    $MNMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Medical Officer Karlin Daniel sold $46,075 worth of shares (6,836 units at $6.74), decreasing direct ownership by 2% to 446,177 units (SEC Form 4)

      4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)

      3/26/25 5:00:17 PM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Chief Executive Officer Barrow Robert sold $142,942 worth of shares (21,208 units at $6.74), decreasing direct ownership by 2% to 856,556 units (SEC Form 4)

      4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)

      3/26/25 5:00:18 PM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Chief Legal Officer Sullivan Mark sold $44,322 worth of shares (6,576 units at $6.74), decreasing direct ownership by 2% to 316,621 units (SEC Form 4)

      4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)

      3/26/25 5:00:13 PM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care

    $MNMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Mind Medicine (MindMed) Inc.

      SC 13G/A - Mind Medicine (MindMed) Inc. (0001813814) (Subject)

      11/14/24 4:05:16 PM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G filed by Mind Medicine (MindMed) Inc.

      SC 13G - Mind Medicine (MindMed) Inc. (0001813814) (Subject)

      3/21/24 4:05:38 PM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G filed by Mind Medicine (MindMed) Inc.

      SC 13G - Mind Medicine (MindMed) Inc. (0001813814) (Subject)

      3/15/24 4:08:37 PM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care

    $MNMD
    Financials

    Live finance-specific insights

    See more
    • MindMed Reports First Quarter 2025 Financial Results and Recent Business Updates

      --Dosed first patient in Emerge, the first Phase 3 study of MM120 Orally Disintegrating Tablet (ODT) in Major Depressive Disorder (MDD); 12-week topline data anticipated in 2H 2026-- --Enrollment on track in Phase 3 Voyage and Panorama studies of MM120 (ODT) in Generalized Anxiety Disorder (GAD); 12-week topline data anticipated in 1H 2026 for Voyage and 2H 2026 for Panorama-- --Company to host a conference call today at 8:00 a.m. EDT-- Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced its first quarter 2025 financial results and pro

      5/8/25 7:00:00 AM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • MindMed to Report First Quarter 2025 Financial Results on May 8, 2025

      Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it will host a live webcast at 8:00 a.m. ET on Thursday, May 8, 2025 to report financial results for the first quarter ended March 31, 2025, and discuss recent business updates. Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the Investor Relations section of the MindMed website, ir.mindmed.co, and archived for at least 30 days after the webca

      4/24/25 7:00:00 AM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • MindMed Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Updates

      --First Patients Dosed in Phase 3 Voyage and Panorama studies of MM120 Orally Disintegrating Tablet (ODT) in Generalized Anxiety Disorder (GAD); 12-week topline data anticipated in 1H 2026 for Voyage and 2H 2026 for Panorama-- --On track to initiate Emerge, the first Phase 3 study of MM120 ODT in Major Depressive Disorder (MDD) in 1H of 2025-- --Raised approximately $250 million in gross proceeds through two equity financings in 2024; cash and cash equivalents of $273.7 million as of December 31, 2024, expected to fund operations into 2027 and extend at least 12 months beyond the first Phase 3 topline data readout for MM120 ODT in GAD-- --Company to host a conference call today at 8:00

      3/6/25 7:00:00 AM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care

    $MNMD
    SEC Filings

    See more
    • SEC Form 10-Q filed by Mind Medicine (MindMed) Inc.

      10-Q - Mind Medicine (MindMed) Inc. (0001813814) (Filer)

      5/8/25 7:25:20 AM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Mind Medicine (MindMed) Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Mind Medicine (MindMed) Inc. (0001813814) (Filer)

      5/8/25 7:15:09 AM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form D filed by Mind Medicine (MindMed) Inc.

      D - Mind Medicine (MindMed) Inc. (0001813814) (Filer)

      5/5/25 4:06:27 PM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care